While the treatment and management of hyperglycemia especially in T2D has always been based on insulin response, emerging evidence suggests that inhibition of glucagon signalling presents a potential approach to the maintenance of normal glucose levels. The gene discussed is INS; the disease is type 2 diabetes mellitus.